Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression

References

• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335–10. doi:10.1172/JCI83871.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018–28
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311–9
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105–16
   PubMed Web of Science ®Google Scholar
• Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. Journal of Clinical Oncology 1986; 4:900–5 6 doi:10.1200/JCO.1986.4.6.900
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329:1608–14
   Google Scholar
• Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016;40:96–102. doi:10.1016/j.coi.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Amsen D, van Gisbergen K, Hombrink P, van Lier RAW. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol. 2018;19:538–46. doi:10.1038/s41590-018-0114-2.
   PubMed Web of Science ®Google Scholar
• Hutmacher C, Gonzalo Nunez N, Liuzzi AR, Becher B, Neri D. Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8(+) T cells. Cancer Immunol Res. 2019;7:572–83. doi:10.1158/2326-6066.CIR-18-0566.
   PubMed Web of Science ®Google Scholar
• Puca E, Probst P, Stringhini M, Murer P, Pellegrini G, Cazzamalli S, Hutmacher C, Gouyou B, Wulhfard S, Matasci M, et al. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer. 2020;146:2518–30. doi:10.1002/ijc.32603.
   PubMed Web of Science ®Google Scholar
• Hemmerle T, Neri D. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer. 2014;134:467–77. doi:10.1002/ijc.28359.
   PubMed Web of Science ®Google Scholar
• Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A. 2015;112:3320–25. doi:10.1073/pnas.1416159112.
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002;99:1659–65. doi:10.1182/blood.V99.5.1659.
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A. 1999;96:8591–96. doi:10.1073/pnas.96.15.8591.
   PubMed Web of Science ®Google Scholar
• Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, Lichtenstein A, Morrison SL. Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. J Interferon Cytokine Res. 2015;35:281–91. doi:10.1089/jir.2014.0125.
   PubMed Web of Science ®Google Scholar
• Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res. 2007;13:2758–67. doi:10.1158/1078-0432.CCR-06-2343.
   PubMed Web of Science ®Google Scholar
• Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsieh S-L, Nagata S, Ni J, Chen L. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000;164:4105–10. doi:10.4049/jimmunol.164.8.4105.
   PubMed Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu Y-X, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141–49. doi:10.1038/ni1029.
   PubMed Web of Science ®Google Scholar
• Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8:21–30
   PubMed Web of Science ®Google Scholar
• Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. The Journal of experimental medicine 1999; 189:403–12
   Google Scholar
• Lu TT, Browning JL. Role of the lymphotoxin/LIGHT system in the development and maintenance of reticular networks and vasculature in lymphoid tissues. Front Immunol. 2014;5:47. doi:10.3389/fimmu.2014.00047.
   PubMed Web of Science ®Google Scholar
• Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer research 2017; 77:1880–91
   PubMed Web of Science ®Google Scholar
• Hemmerle T, Hess C, Venetz D, Neri D. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily. J Biotechnol. 2014;172:73–76. doi:10.1016/j.jbiotec.2013.12.010.
   PubMed Web of Science ®Google Scholar
• Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology. 2016;5:e1238540. doi:10.1080/2162402X.2016.1238540.
   PubMed Web of Science ®Google Scholar
• Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Muller M, Sefrin JP, Schröder M, Sykora J, Fricke H. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcgammaR-binding functionality. J Immunother Cancer. 2019;7:191. doi:10.1186/s40425-019-0671-4.
   PubMed Web of Science ®Google Scholar
• Venetz D, Hess C, Lin CW, Aebi M, Neri D. Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies. Proc Natl Acad Sci U S A. 2015;112:2000–05. doi:10.1073/pnas.1416694112.
   PubMed Web of Science ®Google Scholar
• Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinić J. Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng. 2003;83:321–34. doi:10.1002/bit.10673.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36:477–89. doi:10.1097/01.cji.0000436722.46675.4a.
   PubMed Web of Science ®Google Scholar
• Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, et al. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunol Res 2017; 5:29–41
   PubMed Web of Science ®Google Scholar
• Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem. 2006;281:13964–71. doi:10.1074/jbc.M601553200.
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu Y-X. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29:285–96. doi:10.1016/j.ccell.2016.02.004.
   PubMed Web of Science ®Google Scholar
• Fan Z, Yu P, Wang Y, Wang Y, Fu ML, Liu W, Sun Y, Fu Y-X. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood. 2006;107:1342–51. doi:10.1182/blood-2005-08-3485.
   PubMed Web of Science ®Google Scholar
• Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer. 2008;122:2405–13. doi:10.1002/ijc.23408.
   PubMed Web of Science ®Google Scholar
• Probst P, Kopp J, Oxenius A, Colombo MP, Ritz D, Fugmann T, Neri D. Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8(+) T-cell Recognition of a Retroviral Antigen. Cancer research 2017; 77:3644–54
   Google Scholar
• Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J, Chervonsky AV, Fu Y-X. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity. 2006;25:499–509. doi:10.1016/j.immuni.2006.06.016.
   PubMed Web of Science ®Google Scholar
• Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE. Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. Oncotarget. 2018;9:11322–35.
   PubMedGoogle Scholar
• Del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol. 2010;87:223–35. doi:10.1189/jlb.0809590.
   PubMed Web of Science ®Google Scholar
• Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res. 2012;18:4092–103. doi:10.1158/1078-0432.CCR-12-0282.
   PubMed Web of Science ®Google Scholar
• Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 2007;67:4940–48. doi:10.1158/0008-5472.CAN-07-0283.
   PubMed Web of Science ®Google Scholar
• Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996; 93:9730–5
   PubMed Web of Science ®Google Scholar
• Laumont CM, Vincent K, Hesnard L, Audemard E, Bonneil E, Laverdure JP, Gendron P, Courcelles M, Hardy M-P, Côté C. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018;10:10. doi:10.1126/scitranslmed.aau5516.
   Web of Science ®Google Scholar
• Probst P, Stringhini M, Ritz D, Fugmann T, Neri D. Antibody-based delivery of TNF to the tumor neovasculature potentiates the therapeutic activity of a peptide anticancer vaccine. Clin Cancer Res. 2019;25:698–709. doi:10.1158/1078-0432.CCR-18-1728.
   PubMed Web of Science ®Google Scholar
• Rybak JN, Roesli C, Kaspar M, Villa A, Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 2007;67:10948–57. doi:10.1158/0008-5472.CAN-07-1436.
   PubMed Web of Science ®Google Scholar
• Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res. 2009;33:1718–22. doi:10.1016/j.leukres.2009.06.025.
   PubMed Web of Science ®Google Scholar
• Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009; 11:R142
   Google Scholar
• Putelli A, Kiefer JD, Zadory M, Matasci M, Neri D. A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo. J Mol Biol. 2014;426:3606–18.
   PubMed Web of Science ®Google Scholar
• Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol. 2011;154:84–92. doi:10.1016/j.jbiotec.2011.04.003.
   PubMed Web of Science ®Google Scholar
• Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM. A simple high-yielding process for transient gene expression in CHO cells. J Biotechnol. 2011;153:22–26.
   PubMed Web of Science ®Google Scholar
• Zhang MC, Liu HP, Demchik LL, Zhai YF, Yang DJ. LIGHT sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways. Cell Res. 2004;14:117–24. doi:10.1038/sj.cr.7290210.
   PubMed Web of Science ®Google Scholar